S&P 500   4,274.04
DOW   33,980.32
QQQ   328.49
Agilent Technologies Proves Its Worth VS Illumina 
Market Wizard Who Accurately Predicted 2022 Market Collapse Has Shocking New Forecast (Ad)
Target’s Results Cap Upside Potential For Retail Stocks 
Wind energy boom and golden eagles collide in the US West
Lowe’s Stands Out Amid Q2 Retail Reports 
Trading Millionaire Reveals, “2008 Was My Most Profitable Year” (Ad)
Egypt's central bank governor resigns as economic woes mount
Target takes a hit after heavy discounts to clear inventory
Stocks slip on Wall Street, erasing weekly gains for S&P 500
Trading Millionaire Reveals, “2008 Was My Most Profitable Year” (Ad)
S&P 500   4,274.04
DOW   33,980.32
QQQ   328.49
Agilent Technologies Proves Its Worth VS Illumina 
Market Wizard Who Accurately Predicted 2022 Market Collapse Has Shocking New Forecast (Ad)
Target’s Results Cap Upside Potential For Retail Stocks 
Wind energy boom and golden eagles collide in the US West
Lowe’s Stands Out Amid Q2 Retail Reports 
Trading Millionaire Reveals, “2008 Was My Most Profitable Year” (Ad)
Egypt's central bank governor resigns as economic woes mount
Target takes a hit after heavy discounts to clear inventory
Stocks slip on Wall Street, erasing weekly gains for S&P 500
Trading Millionaire Reveals, “2008 Was My Most Profitable Year” (Ad)
S&P 500   4,274.04
DOW   33,980.32
QQQ   328.49
Agilent Technologies Proves Its Worth VS Illumina 
Market Wizard Who Accurately Predicted 2022 Market Collapse Has Shocking New Forecast (Ad)
Target’s Results Cap Upside Potential For Retail Stocks 
Wind energy boom and golden eagles collide in the US West
Lowe’s Stands Out Amid Q2 Retail Reports 
Trading Millionaire Reveals, “2008 Was My Most Profitable Year” (Ad)
Egypt's central bank governor resigns as economic woes mount
Target takes a hit after heavy discounts to clear inventory
Stocks slip on Wall Street, erasing weekly gains for S&P 500
Trading Millionaire Reveals, “2008 Was My Most Profitable Year” (Ad)
S&P 500   4,274.04
DOW   33,980.32
QQQ   328.49
Agilent Technologies Proves Its Worth VS Illumina 
Market Wizard Who Accurately Predicted 2022 Market Collapse Has Shocking New Forecast (Ad)
Target’s Results Cap Upside Potential For Retail Stocks 
Wind energy boom and golden eagles collide in the US West
Lowe’s Stands Out Amid Q2 Retail Reports 
Trading Millionaire Reveals, “2008 Was My Most Profitable Year” (Ad)
Egypt's central bank governor resigns as economic woes mount
Target takes a hit after heavy discounts to clear inventory
Stocks slip on Wall Street, erasing weekly gains for S&P 500
Trading Millionaire Reveals, “2008 Was My Most Profitable Year” (Ad)
NASDAQ:SAGE

Sage Therapeutics - SAGE Stock Forecast, Price & News

$43.12
+0.25 (+0.58%)
(As of 08/17/2022 12:00 AM ET)
Add
Compare
Today's Range
$41.98
$43.41
50-Day Range
$31.36
$43.27
52-Week Range
$27.36
$47.75
Volume
519,669 shs
Average Volume
706,718 shs
Market Capitalization
$2.56 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$54.47

Sage Therapeutics MarketRank™ Forecast

Analyst Rating
Hold
2.43 Rating Score
Upside/​Downside
26.3% Upside
$54.47 Price Target
Short Interest
Bearish
6.79% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.79
Upright™ Environmental Score
News Sentiment
0.40mentions of Sage Therapeutics in the last 14 days
Based on 3 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($8.68) to ($7.77) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.14 out of 5 stars

Medical Sector

624th out of 1,122 stocks

Pharmaceutical Preparations Industry

312th out of 551 stocks

SAGE stock logo

About Sage Therapeutics (NASDAQ:SAGE) Stock

Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive steroid, which is in Phase III clinical trials for treating PPD, major depressive disorders, treatment resistant disorders, generalized anxiety disorders, and bipolar depression; and SAGE-324, a compound that is in Phase II clinical trial to treat essential tremors, as well as has completed Phase I clinical trial for epilepsy and Parkinson's diseases. In addition, its product pipeline comprises SAGE-718, an oxysterol-based positive allosteric modulator of the NMDA receptor, which has completed Phase I clinical trial for the treatment of depression, Huntington's disease, Alzheimer's disease, attention deficit hyperactivity disorder, schizophrenia, and neuropathic pain. Sage Therapeutics, Inc. has a strategic collaboration with Shionogi & Co., Ltd. for the development and commercialization of zuranolone in Japan, Taiwan, and South Korea; and a collaboration and license agreement with Biogen MA Inc. to jointly develop and commercialize SAGE-217 and SAGE-324 products. The company was formerly known as Sterogen Biopharma, Inc. and changed its name to Sage Therapeutics, Inc. in September 2011. Sage Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.

Wall Street Analyst Weigh In

SAGE has been the subject of a number of recent analyst reports. Stifel Nicolaus decreased their price target on shares of Sage Therapeutics from $58.00 to $56.00 in a research report on Tuesday, August 2nd. The Goldman Sachs Group decreased their price objective on shares of Sage Therapeutics from $85.00 to $73.00 and set a "buy" rating for the company in a report on Tuesday, May 24th. SVB Leerink decreased their price objective on shares of Sage Therapeutics from $50.00 to $40.00 and set a "market perform" rating for the company in a report on Monday, July 11th. Mizuho cut their price objective on shares of Sage Therapeutics from $41.00 to $37.00 in a research note on Wednesday, May 4th. Finally, StockNews.com upgraded shares of Sage Therapeutics from a "sell" rating to a "hold" rating in a research report on Wednesday, August 3rd. Nine research analysts have rated the stock with a hold rating and six have issued a buy rating to the company. Based on data from MarketBeat, Sage Therapeutics presently has an average rating of "Hold" and an average price target of $54.47.

Sage Therapeutics Price Performance

SAGE Stock traded up $0.25 during midday trading on Wednesday, reaching $43.12. 519,669 shares of the stock were exchanged, compared to its average volume of 706,718. The stock has a market capitalization of $2.56 billion, a PE ratio of -5.06 and a beta of 1.43. Sage Therapeutics has a 52 week low of $27.36 and a 52 week high of $47.75. The company has a fifty day moving average price of $35.94 and a 200 day moving average price of $35.17.

Sage Therapeutics (NASDAQ:SAGE - Get Rating) last issued its quarterly earnings data on Tuesday, August 2nd. The biopharmaceutical company reported ($2.13) earnings per share for the quarter, missing analysts' consensus estimates of ($2.12) by ($0.01). The firm had revenue of $1.50 million for the quarter, compared to the consensus estimate of $1.77 million. Sage Therapeutics had a negative return on equity of 30.10% and a negative net margin of 8,162.17%. The company's revenue was down 8.6% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($1.83) EPS. As a group, analysts anticipate that Sage Therapeutics will post -8.68 earnings per share for the current fiscal year.

Receive SAGE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Sage Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

SAGE Stock News Headlines

Sage Therapeutics: Q2 Earnings Insights
See More Headlines
Receive SAGE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Sage Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

SAGE Company Calendar

Last Earnings
8/02/2022
Today
8/17/2022
Next Earnings (Estimated)
11/01/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:SAGE
Employees
471
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$54.47
High Stock Price Forecast
$85.00
Low Stock Price Forecast
$37.00
Forecasted Upside/Downside
+26.3%
Consensus Rating
Hold
Rating Score (0-4)
2.43
Research Coverage
14 Analysts

Profitability

Net Income
$-457,890,000.00
Net Margins
-8,162.17%
Pretax Margin
-8,162.17%

Debt

Sales & Book Value

Annual Sales
$6.31 million
Book Value
$25.31 per share

Miscellaneous

Free Float
56,570,000
Market Cap
$2.56 billion
Optionable
Optionable
Beta
1.43

Key Executives

  • Mr. Barry E. Greene (Age 59)
    Pres, CEO & Director
    Comp: $1.25M
  • Ms. Kimi E. Iguchi CPA (Age 60)
    CFO & Treasurer
    Comp: $621.17k
  • Dr. Albert J. Robichaud Ph.D. (Age 61)
    Chief Scientific Officer
    Comp: $661.68k
  • Dr. Jeffrey M. Jonas M.D. (Age 69)
    Chief Innovation Officer, Chair of the Science & Technology Forum and Director
    Comp: $923.01k
  • Mr. Christopher Benecchi (Age 50)
    Chief Commercial Officer
    Comp: $389.35k
  • Mr. Matt Lasmanis
    Chief Technology & Innovation Officer
  • Helen Rubinstein
    Investor Relations Officer
  • Ms. Anne Marie Cook Esq. (Age 60)
    Sr. VP, Gen. Counsel & Sec.
  • Ms. Erin E. Lanciani (Age 53)
    Chief People & Experience Officer
  • Dr. Amy Schacterle Ph.D.
    Sr. VP of R&D Strategy and Bus. Management













SAGE Stock - Frequently Asked Questions

Should I buy or sell Sage Therapeutics stock right now?

14 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Sage Therapeutics in the last year. There are currently 8 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" SAGE shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in SAGE, but not buy additional shares or sell existing shares.
View SAGE analyst ratings
or view top-rated stocks.

What is Sage Therapeutics' stock price forecast for 2022?

14 brokers have issued 12 month price targets for Sage Therapeutics' stock. Their SAGE share price forecasts range from $37.00 to $85.00. On average, they predict the company's stock price to reach $54.47 in the next year. This suggests a possible upside of 26.7% from the stock's current price.
View analysts price targets for SAGE
or view top-rated stocks among Wall Street analysts.

How have SAGE shares performed in 2022?

Sage Therapeutics' stock was trading at $42.54 at the beginning of the year. Since then, SAGE shares have increased by 1.1% and is now trading at $42.99.
View the best growth stocks for 2022 here
.

When is Sage Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 1st 2022.
View our SAGE earnings forecast
.

How were Sage Therapeutics' earnings last quarter?

Sage Therapeutics, Inc. (NASDAQ:SAGE) issued its quarterly earnings data on Tuesday, August, 2nd. The biopharmaceutical company reported ($2.13) EPS for the quarter, missing analysts' consensus estimates of ($2.12) by $0.01. The biopharmaceutical company had revenue of $1.50 million for the quarter, compared to analysts' expectations of $1.77 million. Sage Therapeutics had a negative net margin of 8,162.17% and a negative trailing twelve-month return on equity of 30.10%. The firm's quarterly revenue was down 8.6% compared to the same quarter last year. During the same period in the previous year, the business earned ($1.83) EPS.

What other stocks do shareholders of Sage Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Sage Therapeutics investors own include NVIDIA (NVDA), AbbVie (ABBV), Micron Technology (MU), Alibaba Group (BABA), Advanced Micro Devices (AMD), Gilead Sciences (GILD), Netflix (NFLX), Roku (ROKU), QUALCOMM (QCOM) and Bristol-Myers Squibb (BMY).

What is Sage Therapeutics' stock symbol?

Sage Therapeutics trades on the NASDAQ under the ticker symbol "SAGE."

Who are Sage Therapeutics' major shareholders?

Sage Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional investors include FMR LLC (10.06%), State Street Corp (4.94%), Price T Rowe Associates Inc. MD (3.50%), JPMorgan Chase & Co. (2.61%), Point72 Asset Management L.P. (2.12%) and Palo Alto Investors LP (1.43%). Insiders that own company stock include Albert Robichaud, Barry E Greene, Barry E Greene, George Golumbeski, James M Frates and Jeffrey M Jonas.
View institutional ownership trends
.

How do I buy shares of Sage Therapeutics?

Shares of SAGE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Sage Therapeutics' stock price today?

One share of SAGE stock can currently be purchased for approximately $42.99.

How much money does Sage Therapeutics make?

Sage Therapeutics (NASDAQ:SAGE) has a market capitalization of $2.55 billion and generates $6.31 million in revenue each year. The biopharmaceutical company earns $-457,890,000.00 in net income (profit) each year or ($8.53) on an earnings per share basis.

How many employees does Sage Therapeutics have?

The company employs 471 workers across the globe.

How can I contact Sage Therapeutics?

Sage Therapeutics' mailing address is 215 FIRST STREET, CAMBRIDGE MA, 02142. The official website for the company is www.sagerx.com. The biopharmaceutical company can be reached via phone at (617) 299-8380, via email at ir@sagerx.com, or via fax at 617-299-8379.

This page (NASDAQ:SAGE) was last updated on 8/18/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.